{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anticoagulant+drugs&page=5",
    "query": {
      "intervention": "Anticoagulant drugs",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 235,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anticoagulant+drugs&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anticoagulant+drugs&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T23:15:02.535Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06455488",
      "title": "MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ventricular Tachycardia"
      ],
      "interventions": [
        {
          "name": "Ventricular Tachycardia Ablation",
          "type": "PROCEDURE"
        },
        {
          "name": "ICD Implant",
          "type": "DEVICE"
        },
        {
          "name": "Antiarrhythmic drug",
          "type": "DRUG"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Cardioversion",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "CorVita Science Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2020-07-20",
      "completion_date": "2030-07-20",
      "has_results": false,
      "last_update_posted_date": "2024-06-12",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06455488"
    },
    {
      "nct_id": "NCT03950076",
      "title": "EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intracranial Hemorrhages",
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Non-anticoagulant medical therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Population Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 948,
      "start_date": "2019-09-20",
      "completion_date": "2026-07-22",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 10,
      "location_summary": "Elk Grove Village, Illinois • Lisle, Illinois • New Orleans, Louisiana + 7 more",
      "locations": [
        {
          "city": "Elk Grove Village",
          "state": "Illinois"
        },
        {
          "city": "Lisle",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Queens",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03950076"
    },
    {
      "nct_id": "NCT00074620",
      "title": "A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Failure",
        "Vascular Graft Occlusion"
      ],
      "interventions": [
        {
          "name": "PEG-hirudin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Speedel Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 260,
      "start_date": "2003-11",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2007-10-05",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074620"
    },
    {
      "nct_id": "NCT02653092",
      "title": "Reprometabolic Syndrome Mediates Subfertility in Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Infertility",
        "Hypogonadotropic Hypogonadotropism",
        "Hyperinsulinemia"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Intralipid",
          "type": "DRUG"
        },
        {
          "name": "Dextrose",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        },
        {
          "name": "GnRH",
          "type": "DRUG"
        },
        {
          "name": "Hyperinsulinemic Euglycemic Clamp",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "38 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 38 Years · Female only"
      },
      "enrollment_count": 84,
      "start_date": "2016-06",
      "completion_date": "2026-12-11",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653092"
    },
    {
      "nct_id": "NCT02145507",
      "title": "Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blood Donors"
      ],
      "interventions": [
        {
          "name": "SOLX (Investigational)",
          "type": "DRUG"
        },
        {
          "name": "AS-3 (Control)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Haemonetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2014-04",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Norfolk, Virginia",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145507"
    },
    {
      "nct_id": "NCT03301779",
      "title": "Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Whole Blood Donation and Leukoreduction"
      ],
      "interventions": [
        {
          "name": "Hemanext Red Blood Cell Processing System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Hemanext",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2017-11-27",
      "completion_date": "2019-03-06",
      "has_results": true,
      "last_update_posted_date": "2020-06-23",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Norfolk, Virginia • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301779"
    },
    {
      "nct_id": "NCT04066933",
      "title": "Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Complex Regional Pain Syndromes",
        "Neuralgia",
        "Thoracic Outlet Neurologic Syndrome"
      ],
      "interventions": [
        {
          "name": "A2M enriched plasma",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Neurological Associates of West Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "23 Years to 77 Years"
      },
      "enrollment_count": 60,
      "start_date": "2018-09-24",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04066933"
    },
    {
      "nct_id": "NCT07699796",
      "title": "Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Venous Thrombosis Deep (Limbs)",
        "Venous Insufficiency (Chronic)(Peripheral)",
        "Varicose Veins Leg",
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heart, Artery, and Vein Center of Fresno",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 564,
      "start_date": "2018-03-06",
      "completion_date": "2021-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07699796"
    },
    {
      "nct_id": "NCT02744092",
      "title": "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Venous Thromboembolism",
        "Deep Vein Thrombosis (DVT)",
        "Pulmonary Embolism (PE)",
        "Blood Clot"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Fondaparinux",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance Foundation Trials, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 811,
      "start_date": "2016-12-13",
      "completion_date": "2021-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 151,
      "location_summary": "Chula Vista, California • Fremont, California • Fresno, California + 104 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02744092"
    },
    {
      "nct_id": "NCT01092455",
      "title": "Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Dialysis"
      ],
      "interventions": [
        {
          "name": "Heparin N reduction",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Randolph Quinn",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2009-12",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2011-09-02",
      "last_synced_at": "2026-10-13T23:15:02.535Z",
      "location_count": 8,
      "location_summary": "New Haven, Connecticut • New York, New York • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01092455"
    }
  ]
}